When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms

Therapeutic Advances in Hematology

Volumn 2, Issue 1, 2011, Pages 11-19

  Oh, Stephen T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

essential thrombocythemia; JAK STAT; JAK2 V617F; LNK; myeloproliferative neoplasms; polycythemia vera; primary myelofibrosis

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE; LNK PROTEIN; MUTANT PROTEIN; PLECKSTRIN; STAT PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; GENE MUTATION; HEMATOPOIESIS; HUMAN; MISSENSE MUTATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEGATIVE FEEDBACK; NONHUMAN; PATHOGENESIS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOP CODON; THROMBOCYTHEMIA; WILD TYPE;

EID: 84993724886     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620710393391     Document Type: Review

References (49)

1. Ania B.J. Suman V.J. Sobell J.L. Codd M.B. Silverstein M.N. Melton L.J. III (1994) Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 47: 89–93.
2. Antonioli E. Guglielmelli P. Poli G. Bogani C. Pancrazzi A. Longo G. et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93: 41–48.
3. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
4. Bersenev A. Wu C. Balcerek J. Jing J. Kundu M. Blobel G.A. et al (2010) LNK constrains myeloproliferative diseases in mice. J Clin Invest 120: 2058–2069.
5. Bersenev A. Wu C. Balcerek J. Tong W. (2008) LNK controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 118 (8): 2832–2844.
6. Bumm T. Elsea C. Corbin A. Loriaux M. Sherbenou D. Wood L. et al (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66: 11156–11165.
7. Buza-Vidas N. Antonchuk J. Qian H. Månsson R. Luc S. Zandi S. et al (2006) Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 20: 2018–2023.
8. Campbell P. Baxter E. Beer P. Scott L. Bench A. Huntly B. et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108: 3548–3555.
9. Ema H. Sudo K. Seita J. Matsubara A. Morita Y. Osawa M. et al (2005) Quantification of self-renewal capacity in single hematopoietic stem cells from normal and LNK-deficient mice. Dev Cell 8: 907–914.
10. Gery S. Cao Q. Gueller S. Xing H. Tefferi A. Koeffler H.P. (2009) LNK inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 85: 957–965.
11. Gery S. Gueller S. Chumakova K. Kawamata N. Liu L. Koeffler H.P. (2007) Adaptor protein LNK negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110: 3360–3364.
12. Huang X. Li Y. Tanaka K. Moore K.G. Hayashi J.I. (1995) Cloning and characterization of LNK, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 92: 11618–11622.
13. Ihle J. Gilliland D. (2007) Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17: 8–14.
14. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
15. Jamieson C.H. Gotlib J. Durocher J.A. Chao M.P. Mariappan M.R. Lay M. et al (2006) The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 103: 6224–6229.
16. Kisseleva T. Bhattacharya S. Braunstein J. Schindler C.W. (2002) Signaling through the JAK / STAT pathway, recent advances and future challenges. Gene 285: 1–24.
17. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
18. Lacout C. Pisani D.F. Tulliez M. Gachelin F.M. Vainchenker W. Villeval J.L. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652–1660.
19. Lasho T.L. Pardanani A. Tefferi A. (2010) LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 363: 1189–1190.
20. Levine R. Wadleigh M. Cools J. Ebert B. Wernig G. Huntly B.J. et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
21. Levine R. Wernig G. (2006) Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology 510: 233–239.
22. Li Y. He X. Schembri-King J. Jakes S. Hayashi J. (2000) Cloning and characterization of human LNK, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol 164: 5199–5206.
23. Mesa R.A. Silverstein M.N. Jacobsen S.J. Wollan P.C. Tefferi A. (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Hematol 61: 10–15.
24. Neubauer H. Cumano A. Muller M. Wu H. Huffstadt U. Pfeffer K. (1998) JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397–409.
25. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr et al (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
26. Pardanani A. Lasho T. Finke C. Hanson C. Tefferi A. (2007) Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21: 1960–1963.
27. Pardanani A. Lasho T. Finke C. Oh S.T. Gotlib J. Tefferi A. (2010) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia [ePub August 2010].
28. Pardanani A. Levine R. Lasho T. Pikman Y. Mesa R. Wadleigh M. et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (10): 3472–3476.
29. Parganas E. Wang D. Stravopodis D. Topham D.J. Marine J.C. Teglund S. et al (1998) JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385–395.
30. Pietra D. Li S. Brisci A. Passamonti F. Rumi E. Theocharides A. et al (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111: 1686–1689.
31. Pikman Y. Lee B.H. Mercher T. McDowell E. Ebert B. Gozo M. et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270–e270.
32. Rudd C.E. (2001) LNK adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE 85: PE1–PE1.
33. Scott L.M. Tong W. Levine R. Scott M.A. Beer P.A. Stratton M.R. et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
34. Shide K. Shimoda H. Kumano T. Karube K. Kameda T. Takenaka K. et al (2008) Development of ET, primary myelofibrosis and PV in mice expressing JAK2V617F. Leukemia 22: 87–95.
35. Simon C. Dondi E. Chaix A. de Sepulveda P. Kubiseski T. Varin-Blank N. et al (2008) LNK adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112: 4039–4047.
36. Takaki S. Morita H. Tezuka Y. Takatsu K. (2002) Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, LNK. J Exp Med 195: 151–160.
37. Takaki S. Sauer K. Iritani B.M. Chien S. Ebihara Y. Tsuji K. et al (2000) Control of B cell production by the adaptor protein LNK. Definition of a conserved family of signal-modulating proteins. Immunity 13: 599–609.
38. Takaki S. Watts J.D. Forbush K.A. Nguyen N.T. Hayashi J. Alberola-Ila J. et al (1997) Characterization of LNK. An adaptor protein expressed in lymphocytes. J Biol Chem 272: 14562–14570.
39. Tefferi A. (2008) JAK and MPL mutations in myeloid malignancies. Leukemia Lymphoma 49: 388–397.
40. Tefferi A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24: 1128–1138.
41. Theocharides A. Boissinot M. Girodon F. Garand R. Teo S. Lippert E. et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110: 375–379.
42. Tiedt R. Hao-Shen H. Sobas M.A. Looser R. Dirnhofer S. Schwaller J. et al (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931–3940.
43. Tong W. Lodish H.F. (2004) LNK inhibits TPO-MPL signaling and TPO-mediated megakaryocytopoiesis. J Exp Med 200: 569–580.
44. Tong W. Zhang J. Lodish H.F. (2005) LNK inhibits erythropoiesis and EPO-dependent JAK2 activation and downstream signaling pathways. Blood 105: 4604–4612.
45. Valentino L. Pierre J. (2006) JAK / STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71: 713–721.
46. Vannucchi A. Antonioli E. Guglielmelli P. Pardanani A. Tefferi A. (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22: 1299–1307.
47. Velazquez L. Cheng A.M. Fleming H.E. Furlonger C. Vesely S. Bernstein A. et al (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in LNK-deficient mice. J Exp Med 195: 1599–1611.
48. Wang Y. Vandris K. Jones A. Cross N. Christos P. Adriano F. et al (2008) JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 22: 1289–1299.
49. Xing S. Wanting T. Zhao W. Ma J. Wang S. Xu X. et al (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109–5117.